WebOfficial Title A Phase Ib/II Placebo Controlled, Double Blinded Study on the Efficacy and Safety of BXQ-350 in Combination with mFOLFOX7 and Bevacizumab in Newly Diagnosed Metastatic Colorectal Carcinoma Details WebMay 25, 2024 · Conclusions: BXQ-350 was well tolerated with no significant dose-limiting toxicities at the highest planed dose level. Preliminary results indicate this novel agent …
Clinical Trials - Bexion Pharmaceuticals
WebJan 10, 2024 · BXQ-350, an "S1P Activator", has demonstrated pre-clinical antitumor effects in vitro and in vivo, particularly in colorectal, brain and other solid tumors. Bexion has completed two single... WebBXQ-350 is a novel anti-neoplastic therapeutic agent configured from two components: Saposin C (SapC), an expressed (human) lysosomal protein, and the phospholipid dioleoylphosphatidyl-serine (DOPS), a cell membrane phospholipid (clinical formulation BXQ-350).Due to the presumed mechanism of action of BXQ-350, Bexion anticipates … foldable table extension woodworking
BXQ-350 Pharmacokinetic/Pharmacodynamic Study in Cancer …
WebJan 11, 2024 · In the trial, all participants will receive BXQ-350 by intravenous (IV) infusion plus standard of care doses of mFOLFOX and bevacizumab. Stage 1 of the study will be … WebApr 12, 2024 · BXQ-350 is a novel anti-neoplastic therapeutic agent configured from two components: Saposin C (SapC), an expressed (human) lysosomal protein, and the … WebA Phase II trial of BXQ-350 in patients with Glioblastoma Multiforme (GBM) Status: Planning. Phase of Trial: Phase II. Latest Information Update: 15 Dec 2024. Price : $35 … eggplant colored blouse